Exagen Inc.

Company Overview

Business Model: Exagen Inc. is a medical technology company focused on the design, development, and commercialization of innovative testing products under its AVISE® brand. These products aid in the differential diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's tests provide clarity in autoimmune disease decision-making, aiming to improve patient clinical outcomes. Revenue is primarily generated through reimbursement from third-party payors (government and commercial), client bill arrangements, and patient self-pay.

Market Position: Exagen Inc. targets approximately 6,000 rheumatologists across the United States with its specialized sales force. Its flagship product, AVISE® CTD, commercially launched in 2012, offers differential diagnosis for connective tissue diseases (CTDs) and other related conditions with overlapping symptoms, leveraging unique biomarkers to improve diagnostic accuracy and speed. The company emphasizes its extensive background in rheumatology, commitment to customer service, and a strong body of peer-reviewed literature supporting its tests' clinical validity and utility. Exagen Inc. aims to become the standard of care in autoimmune disease testing.

Recent Strategic Developments:

• Operational Turnaround: Under new senior leadership since late 2022, Exagen Inc. has executed an operational turnaround, achieving revenue growth of over 20% and gross margin expansion of over 1,200 basis points in fiscal 2024 compared to fiscal 2022. Operating expenses were reduced by over 30%, and net loss decreased by nearly 70% over the same period. Salesforce productivity has nearly doubled, and R&D expenses were reduced by 45% with a focus on near-term pipeline opportunities.
• AVISE® CTD Enhancements: In December 2024, Exagen Inc. completed its 1,000,000th AVISE® CTD test. In January 2025, the company announced conditional approval by the New York State Department of Health (NYSDOH) and commercial launch of new SLE and RA biomarker assays on the AVISE® CTD platform. These new biomarkers are expected to improve clinical utility, average selling price, gross margin, and demand, positioning the company for profitability.
• Strategic Focus: The company's strategy includes expanding AVISE® CTD adoption, developing innovative testing products with clear R&D and commercialization criteria, and delivering sustainable profitable growth through gross margin expansion and operating expense efficiencies.

Geographic Footprint: Exagen Inc.'s primary operations, including its sole clinical laboratory facility and all employees, are located in the United States. Its corporate headquarters and laboratory are in Vista, California, with additional office space in Carlsbad, California. The company's sales force covers 40 territories across five regions: West, Central, Northeast, Southeast, and Mid-Atlantic.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 59.5% (2024) vs. 56.1% (2023)
• Operating Margin: -24.5% (2024) vs. -43.5% (2023)
• Net Margin: -27.2% (2024) vs. -45.1% (2023)

Investment in Growth:

• R&D Expenditure: $5.4 million (9.7% of revenue) in 2024 vs. $4.9 million (9.3% of revenue) in 2023
• Capital Expenditures: $0.5 million in 2024 vs. $0.8 million in 2023
• Strategic Investments: Not explicitly detailed beyond R&D and capital expenditures.

Business Segment Analysis

Exagen Inc. manages its operations and allocates resources as a single reporting segment, focused on the design, development, and commercialization of testing products for complex rheumatic, autoimmune, and autoimmune-related diseases.

Single Operating Segment

Financial Performance:

• Revenue: $55.6 million (+5.9% YoY)
• Gross Margin: 59.5% (vs. 56.1% in prior year)
• Operating Loss: -$13.6 million (improved from -$22.8 million in prior year)
• Key Growth Drivers: Improved average selling price (ASP) for tests, including cash collected related to tests performed in prior periods. The commercial launch of new SLE and RA biomarker assays on the AVISE® CTD platform in January 2025 is expected to drive future ASP gains, gross margin expansion, and increased demand.

Product Portfolio:

• AVISE® CTD (Flagship Product): A comprehensive test for differential diagnosis of various CTDs, including SLE, RA, and Sjögren’s syndrome. It incorporates the proprietary AVISE® Lupus platform and, as of January 2025, new T-Cell Biomarkers and RA Sub-Profile Biomarkers. This product accounted for 91% of revenue in 2024 and 88% in 2023.
• Other AVISE® Tests:
  • AVISE® APS: Aids in diagnosis and management of Antiphospholipid Syndrome (APS).
  • AVISE® Vasculitis AAV: Panel for assessment and monitoring of ANCA-associated vasculitis (AAV).
  • AVISE® Anti-Histone: Test for autoantibodies in drug-induced lupus and SLE patients.
  • AVISE® SLE Prognostic: Panel of autoantibodies for assessing potential complications in SLE (kidney, brain, cardiovascular).
  • AVISE® Anti-CarP: RA prognostic test for identifying patients with increased risk for joint damage (through a distribution agreement with Werfen USA, LLC).
  • AVISE® SLE Monitor: Blood test using CB-CAPs technology to assess SLE disease activity.
  • AVISE® MTX: Patented blood test measuring methotrexate polyglutamates (MTXPG) for RA treatment optimization.
  • AVISE® HCQ: Blood test for objectively monitoring hydroxychloroquine (HCQ) levels in SLE and other CTD patients.

Market Dynamics:

• Competitive Positioning: Exagen Inc. competes with traditional diagnostic methods (e.g., ANA, anti-dsDNA, C3, C4 tests) and commercial laboratories such as ARUP Laboratories, Inc., Laboratory Corporation of America Holdings, the Mayo Clinic, and Quest Diagnostics Incorporated. The company differentiates itself through proprietary technologies (CB-CAPs, T-Cell Biomarkers), extensive clinical validation, and a specialized sales force.
• Key Customer Types: Primarily rheumatologists and their physician assistants in the United States.
• Market Trends: Significant increases in autoimmune incidence, challenges in early and accurate diagnosis due to vague and overlapping symptoms, and a need for highly specific tests.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Exagen Inc. has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain future earnings for business growth. The Amended Loan Agreement also restricts dividend payments.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No authorized programs or amounts for future capital returns are disclosed.

Balance Sheet Position:

• Cash and Equivalents: $22.0 million (2024) vs. $36.5 million (2023)
• Total Debt: $20.2 million (2024) vs. $19.5 million (2023)
• Net Cash Position: $1.8 million (2024) vs. $17.0 million (2023)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The 2017 Term Loan (Amended Loan Agreement) has a maturity date of December 31, 2026, with principal and accrued interest to be repaid in ten equal monthly installments commencing April 2026. Equipment notes payable mature between October 1, 2026, and April 1, 2028.

Cash Flow Generation:

• Operating Cash Flow: -$13.3 million (2024) vs. -$14.5 million (2023)
• Free Cash Flow: -$13.8 million (2024) vs. -$15.3 million (2023)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Exagen Inc. performs all AVISE® tests in its approximately 13,000 square-foot laboratory located in Vista, California. The laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). It is certified for high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) and licensed by California and all states requiring out-of-state licensure, including the NYSDOH. Test results are typically reported within five business days of specimen receipt.

Supply Chain Architecture: Key Suppliers & Partners:

• Diagnostic Testing Supplies: Relies on sole suppliers for critical reagents, equipment, and other materials used in its testing products. For 2024, approximately 71% and 26% of diagnostic testing supplies were purchased from two suppliers, respectively.
• Specimen Collection & Transportation Kits: Purchases components from sole-source suppliers.
• Fulfillment Center: Relies on a sole third-party fulfillment center in Georgia to supply healthcare providers with testing products.

Facility Network:

• Manufacturing/Laboratory: Approximately 13,000 square feet of office and laboratory space in Vista, California, under a lease expiring in 2027. This facility houses all flow cytometers and the bio-repository of specimens.
• Research & Development: R&D activities are conducted within the Vista, California laboratory.
• Distribution: Supported by a sole third-party fulfillment center in Georgia.
• Office Space: Leases approximately 28,000 square feet of additional office space in Carlsbad, California, under a sublease co-terminus with its other lease expiring in 2027.

Operational Metrics:

• AVISE® CTD Tests Delivered: 122,883 in 2024 (an 11% decline from 137,650 in 2023).
• Total AVISE® CTD Tests: Over 1,000,000 tests completed through December 2024.
• Ordering Healthcare Providers: 2,370 in Q4 2024 (a 1% decrease from Q4 2023).

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Employs a specialized sales force organized into 40 territories across five regions (West, Central, Northeast, Southeast, Mid-Atlantic) to target approximately 6,000 rheumatologists in the United States. Sales representatives have extensive experience in healthcare sales, rheumatology, diagnostics, and/or pharmaceutical sales.
• Inside Sales Force: Maintains an inside sales force to access rheumatologists in rural and outlying areas and increase brand awareness.
• Client Services Department: A centralized, dedicated client services department augments sales and marketing efforts by providing technical training and personalized customer support.
• Digital Platforms: Leverages print and digital advertising, direct marketing, and continuing medical education programs.

Customer Portfolio: Enterprise Customers:

• Targeted Specialists: Primarily rheumatologists and their physician assistants.
• Strategic Partnerships: Collaborates with multiple patient advocacy organizations and medical societies, such as the American College of Rheumatology (ACR). Has established relationships with rheumatology care management organizations ("Super Groups"), with AVISE® MTX included in the clinical guidelines for two of these groups.
• Customer Concentration: Not explicitly detailed for individual customers, but revenue from Medicare comprised 25% of total revenue in 2024 (34% in 2023), and Medicare Advantage comprised 20% in 2024 (17% in 2023). United Healthcare accounted for 10% of revenue in 2024.

Geographic Revenue Distribution:

• United States: All employees and operations are located in the United States. No specific revenue breakdown by U.S. region is provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The industry is characterized by rapid technological changes, frequent new product introductions, and evolving standards of care in the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases. There is a significant and increasing prevalence of autoimmune diseases, with over 40 million suspected cases in the United States. Early and accurate diagnosis is critical due to vague symptoms, flaring/remission, and conditions mimicking autoimmune disease, which can lead to inappropriate medications, irreversible tissue damage, and comorbidities.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Traditional Methods: Broad range of diagnostic, immunology, and chemistry biomarkers (e.g., antinuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA), serum complement biomarkers C3 and C4).
• Commercial Laboratories: ARUP Laboratories, Inc.; Laboratory Corporation of America Holdings; the Mayo Clinic; Quest Diagnostics Incorporated. These companies have existing infrastructures for diagnostic services.
• Regional Clinical Laboratories: Aqtual, Inc.
• In-house Labs: Large, multispecialty group medical clinics, health systems, and academic medical university-based clinics.

Emerging Competitive Threats:

• Companies Developing New Products/Technologies: AMPEL BioSolutions, LLC; DxTerity Diagnostics, Inc.; Genalyte Inc.; Immunovia AB; Oncimmune Holdings plc; Progentec Diagnostics Inc.

Competitive Response Strategy: Exagen Inc. aims to become the standard of care by expanding adoption of AVISE® CTD, continuously developing innovative testing products with superior clinical utility, and delivering sustainable profitable growth. This includes leveraging specialized sales, extensive clinical validation, and strategic R&D investments in proprietary technologies.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Fluctuations in operating results due to market acceptance, reimbursement, timing of new product launches, and competition. The market for testing products is subject to rapid technological changes, frequent new product introductions, and evolving industry standards, which could render current products obsolete.
• Technology Disruption: Risk of current and future testing products becoming obsolete due to rapid technological changes and new product introductions by competitors.
• Customer Concentration: Dependence on rheumatologists for ordering tests; potential for decreased demand if healthcare providers do not order products or if demand is not maintained.
• Reimbursement & Coverage: Significant risk if third-party payors (government and commercial) do not provide adequate coverage and reimbursement, or if policies are breached, rescinded, or modified. Delays in payment or unfavorable medical policies could materially compromise commercial success.

Operational & Execution Risks

• Supply Chain Vulnerabilities:
  • Supplier Dependency: Reliance on sole suppliers for critical reagents, equipment, and materials, and a sole third-party fulfillment center. Interruptions or quality issues could disrupt test processing and product supply.
  • Geographic Concentration: All operations are concentrated in Vista, California, near earthquake faults and fire zones, making the company vulnerable to natural or man-made disasters.
  • Capacity Constraints: Inability to scale testing capacity, expand customer service, billing, and systems processes, or hire sufficient personnel if demand grows, could lead to higher costs or inability to meet demand.
• Information Technology & Data Security: Failures in IT, telephone, or other systems could disrupt operations. Security breaches, data loss, or unauthorized access to sensitive information (PHI, PII, IP) could expose the company to liability, damage reputation, and disrupt business. Increased risk due to remote work and the adoption of AI technologies.
• Billing Complexity: Complex billing processes with various payors, differing requirements, and potential for delays, denials, or overpayment recoupments, impacting revenue and cash flow.
• Key Personnel Loss: Dependence on key members of the senior management team and highly skilled scientists, technicians, and salespeople. Inability to attract and retain such talent could adversely affect business.

Financial & Regulatory Risks

• Market & Financial Risks: History of net losses and negative cash flows; may not achieve or maintain profitability. Requires substantial additional capital, which may not be available on acceptable terms, leading to delays or elimination of programs. Inflationary environment impacting costs of revenue and operating expenses. Cash deposits exceed federally insured limits, posing liquidity risk in case of bank failures.
• Credit & Liquidity: Term loan contains restrictive covenants (e.g., minimum liquidity, revenue targets, limitations on asset disposal, mergers, debt, dividends). Failure to comply could lead to acceleration of debt and foreclosure on assets.
• Regulatory & Compliance Risks:
  • Industry Regulation: Heavily regulated industry (CLIA, CAP, state licensure, FDA, anti-kickback, self-referral, false claims, privacy laws). Non-compliance can result in substantial penalties, fines, exclusion from federal programs, and reputational harm.
  • FDA Regulation of LDTs: The FDA's final rule (effective July 2024) to regulate Laboratory Developed Tests (LDTs) as medical devices could subject Exagen Inc.'s AVISE® tests to premarket review and other device requirements, leading to delays, increased expenses, or inability to commercialize. Ongoing litigation challenges this rule.
  • Data Privacy: Strict federal (HIPAA, HITECH, Information Blocking Rule) and state (CCPA, CPRA, "My Health My Data" Act) privacy and security laws. Non-compliance or perceived failures can result in significant penalties, litigation, and reputational damage. GDPR and U.K. GDPR apply to foreign operations.

Geopolitical & External Risks

• Geopolitical Exposure: Business disruptions from political instability, acts of war (e.g., Ukraine, Middle East), natural disasters (exacerbated by climate change), or public health crises.
• Trade Relations: Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws. Violations can lead to criminal liability and harm business.

Innovation & Technology Leadership

Research & Development Focus: Exagen Inc. collaborates with national experts to guide R&D, focusing on projects with competitive advantages, reimbursement pathways, and established evidence development plans. Core Technology Areas:

• AVISE® Lupus Platform: Proprietary, patent-protected, and clinically validated platform for SLE diagnosis, leveraging Cell-Bound Complement Activation Products (CB-CAPs) technology (EC4d and BC4d) and integrating with eight autoantibodies. Demonstrated 80% sensitivity and 86% specificity for SLE.
• T-Cell Biomarkers: Exclusive, worldwide license from Allegheny Health Network Research Institute (AHN) for TC4d, TIgG, and TIgM, commercially launched in January 2025 as part of AVISE® CTD. Clinically validated for high specificity and enhanced sensitivity for SLE, identifying up to 50% of SLE subjects negative by conventional biomarkers.
• RA Sub-Profile Biomarkers: Anti-RA33 IgA, Anti-RA33 IgG, and Anti-RA33 IgM, added to AVISE® CTD in January 2025, to identify the seronegative RA subgroup, improving timely and targeted treatment.
• PAD4 Biomarkers: Pipeline opportunity for novel diagnostic biomarkers for RA, particularly in seronegative cases, and associated with severe disease phenotypes.
• SLE Disease Activity: Leveraging clinical and laboratory data to identify biomarkers for an AI-developed algorithm to guide treatment decisions and monitor disease activity.
• RA Disease Activity: Screening biorepository of RA patient serum for protein antibody markers to develop an algorithmic solution for predicting RA disease activity.
• Lupus Nephritis Biomarkers: Leveraging intellectual property licensed from Johns Hopkins University (JHU) to develop a urinary protein biomarker test for risk stratification and predicting treatment response in Lupus Nephritis (LN).
• Kidney Damage Biomarkers: Developed a four-protein blood-based panel for sensitive detection of kidney damage in early LN and diabetic nephropathy, outperforming creatinine and eGFR. Expected for Pharma collaborations in early 2025.

Intellectual Property Portfolio:

• Patent Strategy: Focuses on obtaining and maintaining patents for patentable aspects of testing products.
  • AVISE® Lupus Platform: Five issued U.S. patents, three U.S. nonprovisional patent applications, and six foreign patents covering the AVISE® Lupus algorithm, expiring between 2032 and 2034.
  • T-Cell Biomarkers: One issued U.S. patent (US 9,709,564) and a foreign patent application (Brazil) covering methods for SLE diagnosis using CB-CAP bound to a t-cell and t-cell autoantibodies. The U.S. patent expires in 2035.
  • AVISE® MTX: Two U.S. patents (US 7,582,282 and US 7,695,908) related to monitoring methotrexate therapy, expiring in 2026 and 2027, respectively.
• Licensing Programs: Licenses intellectual property from third parties, including AHN and JHU.
• IP Litigation: Material disputes are disclosed in the Legal Proceedings section.

Technology Partnerships:

• Strategic Alliances: Exclusive license agreements with Allegheny Health Network Research Institute (AHN) for T-Cell Biomarkers and Johns Hopkins University (JHU) for Lupus Nephritis urinary protein biomarkers.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company revitalized its senior leadership team in late 2022, including the CEO, CFO, VP of Sales, CMO, and Medical and Laboratory Director.

Board Composition: The board includes: Ana Hooker (Senior Vice President, Chief Laboratory Officer, Exact Sciences Corporation), Scott Kahn, Ph.D. (Director, Rady Children's Institute for Genomic Medicine), Paul Kim (Chief Financial Officer, Fulgent Genetics, Inc.), Bruce Robertson, Ph.D. (Managing Director, H.I.G Capital, LLC), and Frank Stokes (Chief Financial Officer, Castle Biosciences, Inc.). The Audit Committee oversees cybersecurity risk management.

Human Capital Strategy

Workforce Composition:

• Total Employees: 209 as of December 31, 2024 (203 full-time, 6 part-time).
• Geographic Distribution: All employees are located in the United States.
• Skill Mix: 57 in laboratory operations, 13 in research and development, 59 in sales and marketing, and 74 in general and administrative functions.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Focuses on attracting, motivating, and retaining talent at all levels, particularly highly skilled scientists, technicians, and specialized salespeople.
• Retention Metrics: Not explicitly disclosed, but efforts include competitive compensation and benefits packages, and fostering an equitable, inclusive, and empowering environment.
• Employee Value Proposition: Values innovation, passion, data-driven decision making, persistence, and honesty. Provides competitive and comprehensive benefits.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed, but the company aims to build a diverse environment.
• Development Programs: Employees participate in comprehensive disease-level sales training and regular, ongoing training activities and certifications.
• Culture & Engagement: Focuses on employee retention and engagement to support business operations and long-term securityholder interests.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Exagen Inc. created an Environmental, Social and Governance Committee (ESG Committee) in 2022 to review and recommend programs, policies, and practices relating to ESG issues. The ESG Committee meets at least annually.

Business Cyclicality & Seasonality

Demand Patterns: Exagen Inc. expects some seasonal variations in financial results due to factors such as the year-end holiday period, other major holidays, vacation patterns of patients and healthcare providers (including medical conferences), climate and weather conditions (e.g., excess sun exposure causing SLE flares), seasonal conditions affecting medical practices (e.g., influenza outbreaks), and the timing of patient benefit changes, deductibles, and co-insurance limits.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Exagen Inc. operates in a heavily regulated industry, subject to numerous federal, state, local, and foreign laws and regulations. Industry-Specific Regulations:

• Clinical Laboratory Regulation: Certified under CLIA and accredited by CAP. Licensed by California and all states requiring out-of-state licensure, including NYSDOH (which requires product-specific approval for LDTs).
• FDA Oversight of LDTs: Historically, the FDA exercised enforcement discretion over LDTs. However, a final rule effective July 5, 2024, will regulate LDTs under the medical device framework, phasing out enforcement discretion over four years. This could require premarket clearance or approval for Exagen Inc.'s AVISE® tests. Litigation is ongoing challenging this rule.
• Clinical Trials: Conducts research studies involving clinical investigators and human subjects, subject to federal and institutional regulations (e.g., IRB review, informed consent, adverse event reporting).
• Advertising: Subject to federal truth-in-advertising laws (FTC Act) and comparable state consumer protection laws.

Trade & Export Controls:

• Export Restrictions: Subject to U.S. export control and import laws (e.g., Export Administration Regulations, Customs regulations, OFAC sanctions) and foreign anti-bribery laws (e.g., FCPA).

Legal Proceedings:

• Qui Tam Lawsuit: In October 2023, Exagen Inc. settled an investigation with the U.S. Attorney’s Office for the District of Massachusetts related to a qui tam lawsuit, remitting $0.7 million plus interest for historical specimen processing arrangements. The "covered conduct" was dismissed with prejudice. A motion to dismiss the remaining complaint is pending as of February 2024, with Exagen Inc. intending to vigorously defend against the claims.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: -0.3% in 2024 vs. -0.1% in 2023.
• Geographic Tax Planning: Not explicitly detailed beyond federal and state income taxes.
• Tax Reform Impact: Subject to Sections 382 and 383 of the Internal Revenue Code, which limit the ability to use net operating loss (NOL) carryforwards and other tax attributes following an "ownership change." Ownership changes occurred in 2003, 2008, 2012, 2017, and 2019, limiting a significant portion of pre-2018 NOL carryforwards. Federal NOLs generated after 2017 carry forward indefinitely but can only offset 80% of taxable income after December 31, 2020.
• NOL Carryforwards: Federal NOLs of $141.5 million (2024) and $129.8 million (2023). State NOLs of $98.7 million (2024) and $91.0 million (2023).

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains professional liability insurance and information security risk insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance coverage.### Company Overview Business Model: Exagen Inc. is a medical technology company primarily focused on the design, development, and commercialization of a next-generation portfolio of innovative testing products under its AVISE® brand. These products are designed for the differential diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's core value proposition is to provide clarity in autoimmune disease decision-making to improve patient clinical outcomes. Primary revenue generation mechanisms include reimbursement from government payors (Medicare, Medicaid), commercial payors (insurance companies), client bill arrangements (hospitals, other laboratories), and patient self-pay.

Market Position: Exagen Inc. targets approximately 6,000 rheumatologists across the United States. Its flagship product, AVISE® CTD, launched in 2012, enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company leverages proprietary biomarkers to enhance diagnostic accuracy and speed, aiming to become the standard of care in autoimmune disease testing. Exagen Inc. has an extensive background in rheumatology and a commitment to customer service, supported by a significant body of peer-reviewed literature validating its tests.

Recent Strategic Developments:

• Operational Turnaround: Since late 2022, Exagen Inc. has executed an operational turnaround under new senior leadership. This initiative resulted in a 20% revenue growth, over 1,200 basis points of gross margin expansion, over 30% reduction in operating expenses, and nearly 70% reduction in net loss in fiscal 2024 compared to fiscal 2022. Salesforce productivity has nearly doubled, and Research and Development (R&D) expenses were reduced by 45% with a focus on near-term pipeline opportunities.
• AVISE® CTD Enhancements: In December 2024, Exagen Inc. completed its 1,000,000th AVISE® CTD test. In January 2025, the company announced conditional approval by the New York State Department of Health (NYSDOH) and commercial launch of new SLE and RA biomarker assays on the AVISE® CTD platform. These new biomarkers are expected to further improve the clinical utility of AVISE® CTD, leading to improvements in average selling price, gross margin expansion, and increased demand, positioning the company for profitability.
• Strategic Focus: The company's strategy includes expanding the adoption of AVISE® CTD, continuing to develop innovative testing products with clear R&D and commercialization criteria, and achieving sustainable profitable growth through gross margin enhancements and improved operating expense efficiencies.

Geographic Footprint: Exagen Inc.'s operations are entirely based in the United States. Its corporate headquarters and sole clinical laboratory facility are located in Vista, California, occupying approximately 27,000 square feet under a lease expiring in 2027. An additional 28,000 square feet of office space is leased in Carlsbad, California, under a sublease co-terminous with the primary lease in 2027. The company's specialized sales force operates across 40 territories within five regions: West, Central, Northeast, Southeast, and Mid-Atlantic.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 59.5% (2024)
• Operating Margin: -24.5% (2024)
• Net Margin: -27.2% (2024)

Investment in Growth:

• R&D Expenditure: $5.4 million (9.7% of revenue)
• Capital Expenditures: $0.5 million
• Strategic Investments: Not explicitly detailed beyond R&D and capital expenditures.

Business Segment Analysis

Exagen Inc. operates as a single reporting segment, focusing on the design, development, and commercialization of testing products for complex rheumatic, autoimmune, and autoimmune-related diseases.

Single Operating Segment

Financial Performance:

• Revenue: $55.6 million (+5.9% YoY)
• Operating Margin: -24.5% (improved from -43.5% in prior year)
• Key Growth Drivers: The increase in revenue was primarily driven by improved average selling price (ASP), including cash collected related to tests performed in prior periods. This was partially offset by an 11% decrease in AVISE® CTD test volume in 2024 compared to 2023, resulting from revenue cycle management initiatives and a reduction in sales territories initiated in 2022. The commercial launch of new SLE and RA biomarker assays on the AVISE® CTD platform in January 2025 is anticipated to drive future ASP gains, gross margin expansion, and increased demand.

Product Portfolio:

• AVISE® CTD (Flagship Product): A comprehensive test for the differential diagnosis of various CTDs, including SLE, RA, and Sjögren’s syndrome. It incorporates the proprietary AVISE® Lupus platform and, as of January 2025, new T-Cell Biomarkers and RA Sub-Profile Biomarkers. This product accounted for 91% of total revenue in 2024.
• Other AVISE® Tests:
  • AVISE® APS: Aids in the diagnosis and management of Antiphospholipid Syndrome (APS).
  • AVISE® Vasculitis AAV: A testing panel for the assessment and monitoring of ANCA-associated vasculitis (AAV).
  • AVISE® Anti-Histone: A test for autoantibodies to histone proteins found in drug-induced lupus and SLE patients.
  • AVISE® SLE Prognostic: A panel of autoantibodies with predictive value for assessing potential complications in SLE affecting the kidney, brain, and cardiovascular system.
  • AVISE® Anti-CarP: A biomarker-driven RA prognostic test, offered through a distribution agreement with Werfen USA, LLC, to identify RA patients with an increased risk for joint damage.
  • AVISE® SLE Monitor: A blood test employing CB-CAPs technology to assess the condition and disease activity of diagnosed SLE patients.
  • AVISE® MTX: A patented blood test that precisely measures methotrexate polyglutamates (MTXPG), the active metabolite of methotrexate, for optimizing RA treatment.
  • AVISE® HCQ: A blood test designed to objectively monitor hydroxychloroquine (HCQ) levels in patients with SLE and other CTDs.

Market Dynamics:

• Competitive Positioning within Segment: Exagen Inc. competes with traditional diagnostic methods (e.g., ANA, anti-dsDNA, C3, C4 tests) and commercial laboratories such as ARUP Laboratories, Inc., Laboratory Corporation of America Holdings, the Mayo Clinic, and Quest Diagnostics Incorporated. The company differentiates itself through its proprietary AVISE® Lupus platform, T-Cell Biomarkers, extensive clinical validation, and a specialized sales force.
• Key Customer Types and Market Trends: Primary customers are rheumatologists and their physician assistants. The market is driven by the increasing incidence of autoimmune diseases and the challenge of early and accurate diagnosis due to overlapping symptoms, highlighting the need for highly specific and sensitive tests.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Exagen Inc. has never declared or paid cash dividends on its common stock and does not intend to do so in the foreseeable future, prioritizing the retention of future earnings for business growth. The Amended Loan Agreement also currently prohibits cash dividend payments.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No authorized programs or amounts for future capital returns are disclosed.

Balance Sheet Position:

• Cash and Equivalents: $22.0 million (2024) vs. $36.5 million (2023)
• Total Debt: $20.2 million (2024) vs. $19.5 million (2023)
• Net Cash Position: $1.8 million (2024) vs. $17.0 million (2023)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The 2017 Term Loan (Amended Loan Agreement) has a maturity date of December 31, 2026. Principal and accrued interest are to be repaid in ten equal monthly installments commencing April 1, 2026. Equipment notes payable mature between October 1, 2026, and April 1, 2028.

Cash Flow Generation:

• Operating Cash Flow: -$13.3 million (2024) vs. -$14.5 million (2023)
• Free Cash Flow: -$13.8 million (2024) vs. -$15.3 million (2023)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Exagen Inc. operates a single, approximately 13,000 square-foot clinical laboratory in Vista, California. This facility is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). It is certified for high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) and holds licenses from California and all states requiring out-of-state licensure, including the NYSDOH. The laboratory typically reports AVISE® testing results within five business days of specimen receipt.

Supply Chain Architecture: Key Suppliers & Partners:

• Diagnostic Testing Supplies: Exagen Inc. relies on sole suppliers for critical reagents, equipment, and other materials essential for its testing products. In 2024, approximately 71% and 26% of the company's diagnostic testing supplies were sourced from two primary suppliers, respectively.
• Specimen Collection & Transportation Kits: Components for these kits are purchased from sole-source suppliers.
• Fulfillment Center: The company utilizes a sole third-party fulfillment center located in Georgia for supplying healthcare providers with its testing products.

Facility Network:

• Manufacturing/Laboratory: The primary laboratory and corporate headquarters are in Vista, California, under a lease that expires in 2027. This facility houses all flow cytometers, which are critical for detecting CB-CAPs, and the company's bio-repository of patient specimens.
• Research & Development: R&D activities are conducted within the Vista, California laboratory.
• Distribution: Logistics are managed through the sole third-party fulfillment center in Georgia.
• Office Space: An additional 28,000 square feet of office space is leased in Carlsbad, California, with a sublease expiring in 2027.

Operational Metrics:

• AVISE® CTD Tests Delivered: 122,883 in 2024, representing an 11% decrease year-over-year.
• Total AVISE® CTD Tests: Over 1,000,000 tests completed through December 2024.
• Ordering Healthcare Providers: 2,370 in Q4 2024, a 1% decrease year-over-year.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Exagen Inc. employs a specialized sales force, organized into 40 territories across five regions (West, Central, Northeast, Southeast, Mid-Atlantic), to directly target approximately 6,000 rheumatologists in the United States. Sales representatives possess specific technical backgrounds and industry expertise in rheumatology, diagnostics, and/or pharmaceutical sales.
• Inside Sales Force: An inside sales force is maintained to enhance access to rheumatologists in rural and outlying areas and to increase brand awareness among healthcare providers.
• Client Services Department: A centralized, dedicated client services department provides technical training and personalized customer support, augmenting field sales and marketing efforts.
• Digital Platforms: Marketing activities include print and digital advertising, direct marketing, and continuing medical education programs.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The company focuses on building relationships with major rheumatology practices and healthcare systems.
• Strategic Partnerships: Exagen Inc. collaborates with multiple patient advocacy organizations and medical societies, including the American College of Rheumatology (ACR). It has also established strong relationships with rheumatology care management organizations ("Super Groups"), with its AVISE® MTX testing product included in the clinical guidelines for two of these groups.
• Customer Concentration: Revenue from Medicare comprised 25% of total revenue in 2024 (34% in 2023). Medicare Advantage accounted for 20% of revenue in 2024 (17% in 2023). United Healthcare represented 10% of total revenue in 2024.

Geographic Revenue Distribution:

• United States: All revenue is generated within the United States, as all employees and operations are located domestically. No specific regional revenue breakdown is provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The diagnostics industry for autoimmune diseases is characterized by rapid technological advancements, frequent new product introductions, and evolving standards of care. The market addresses a significant and growing patient population, with over 40 million suspected cases of autoimmune diseases in the United States. Challenges include the vagueness and overlapping nature of symptoms, which complicate early and accurate diagnosis, underscoring the need for highly specific and sensitive diagnostic tools to prevent inappropriate treatments and irreversible tissue damage.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Traditional Diagnostic Methods: Standard tests such as antinuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA), and serum complement biomarkers (C3 and C4).
• Commercial Laboratories: Large, established players including ARUP Laboratories, Inc.; Laboratory Corporation of America Holdings; the Mayo Clinic; and Quest Diagnostics Incorporated, which possess extensive infrastructure for diagnostic services.
• Regional Clinical Laboratories: Companies like Aqtual, Inc.
• In-house Laboratories: Clinical laboratories operated by large, multispecialty group medical clinics, health systems, and academic medical universities.

Emerging Competitive Threats:

• New Entrants and Technology Developers: Companies developing new diagnostic, disease, or drug monitoring products, such as AMPEL BioSolutions, LLC; DxTerity Diagnostics, Inc.; Genalyte Inc.; Immunovia AB; Oncimmune Holdings plc; and Progentec Diagnostics Inc.

Competitive Response Strategy: Exagen Inc. aims to maintain and enhance its competitive advantage by continuously innovating and expanding its testing product offerings, demonstrating superior clinical utility through robust clinical validation, securing broad reimbursement, and leveraging its specialized sales and marketing capabilities to drive market acceptance.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Operating results may fluctuate significantly due to factors beyond the company's control, including market acceptance of its testing products, reimbursement policies, timing of new product launches, and competitive landscape changes. The rapid pace of technological change in the diagnostics industry poses a risk of current and future testing products becoming obsolete.
• Technology Disruption: The industry's rapid technological evolution, frequent new product introductions, and evolving standards of care could render Exagen Inc.'s current and future testing products obsolete if the company fails to continuously innovate and expand its offerings.
• Customer Concentration: Commercial success is highly dependent on attaining and maintaining significant market acceptance among rheumatologists, patients, and third-party payors. A decrease in healthcare provider orders or inability to maintain demand could limit revenue.
• Reimbursement & Coverage: The availability of coverage and adequate reimbursement from third-party payors (government and commercial) is critical. Breaches, rescissions, or modifications of contracts or reimbursement policies, or delays in payments, could materially compromise commercial success.

Operational & Execution Risks

• Supply Chain Vulnerabilities:
  • Supplier Dependency: Reliance on sole suppliers for critical reagents, equipment, and materials, as well as a sole third-party fulfillment center, creates vulnerability to supply interruptions, quality issues, or inability to find replacements.
  • Geographic Concentration: The company's sole clinical laboratory facility and corporate headquarters are located in Vista, California, an area prone to earthquakes and fires. Damage or inoperability of this facility would severely disrupt testing services.
  • Capacity Constraints: Inability to scale testing capacity, expand customer service, billing, and systems processes, or attract and retain sufficient qualified personnel (e.g., clinical laboratory scientists) as demand grows could lead to higher costs or inability to meet market demand.
• Information Technology & Data Security: Failures or interruptions in information technology, telephone, or other systems could significantly disrupt operations. Security breaches, loss of data, unauthorized disclosure, or access to sensitive information (including Protected Health Information (PHI), Personally Identifiable Information (PII), and intellectual property) could expose the company to liability, damage its reputation, and disrupt business. The adoption of AI technologies and remote work arrangements may heighten these risks.
• Billing Complexity: The billing process for testing products is complex, time-consuming, and expensive, involving various payors with differing requirements. This complexity can lead to delays, denials, or recoupments of payments, negatively impacting revenue and cash flow.
• Key Personnel Loss: The company's success depends on its ability to attract and retain key members of its executive management team and highly skilled scientific, technical, and sales personnel. Loss of these individuals or inability to attract new talent could adversely affect business strategy execution.

Financial & Regulatory Risks

• Market & Financial Risks: Exagen Inc. has a history of net losses and negative cash flows from operating activities, and expects to incur additional losses. The company requires substantial additional capital to finance planned operations, which may not be available on acceptable terms, potentially forcing delays or elimination of product development and commercialization efforts. Inflationary pressures could adversely affect costs and financial results. Cash deposits exceeding federally insured limits pose a risk in the event of financial institution failures.
• Credit & Liquidity: The Amended Loan Agreement contains restrictive covenants (e.g., minimum liquidity, revenue targets, limitations on asset disposal, mergers, debt, dividends). Failure to comply could result in acceleration of indebtedness and potential foreclosure on assets.
• Regulatory & Compliance Risks:
  • Industry Regulation: The company operates in a heavily regulated industry, subject to CLIA, CAP, state licensure laws, FDA regulations, federal and state anti-kickback laws (including EKRA), physician self-referral prohibitions (Stark Law, PORA), False Claims Act, civil monetary penalties law, and various other healthcare fraud and abuse laws. Non-compliance can result in substantial penalties, fines, imprisonment, exclusion from federal healthcare programs, and reputational harm.
  • FDA Regulation of LDTs: The FDA's final rule, effective July 2024, to regulate Laboratory Developed Tests (LDTs) as medical devices, phases out historical enforcement discretion. This could subject Exagen Inc.'s AVISE® tests to extensive medical device regulatory requirements, including premarket clearance or approval, leading to delays, increased expenses, or inability to commercialize. Ongoing litigation challenges this rule, creating uncertainty.
  • Data Privacy: Compliance with numerous federal (HIPAA, HITECH, Information Blocking Rule) and state (e.g., CCPA, CPRA, Washington's "My Health My Data" Act) privacy and security laws is critical. Non-compliance or perceived failures can result in significant penalties, government investigations, private litigation, and reputational damage. Foreign privacy laws like GDPR and U.K. GDPR also apply to international activities.

Geopolitical & External Risks

• Geopolitical Exposure: Business operations are susceptible to disruptions from geopolitical actions, including acts of war (e.g., current conflicts in Ukraine and the Middle East), political instability, natural disasters (potentially exacerbated by climate change), public health crises, and trade relations.
• Trade Relations: Subject to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws (e.g., FCPA), and anti-money laundering laws. Violations can lead to criminal liability, substantial fines, and harm to business.

Innovation & Technology Leadership

Research & Development Focus: Exagen Inc. engages with national experts to guide its R&D projects, prioritizing initiatives that offer competitive advantages, clear pathways for reimbursement, and established evidence development plans. Core Technology Areas:

• AVISE® Lupus Platform: Focuses on proprietary, patent-protected, and clinically validated methods for SLE diagnosis, leveraging Cell-Bound Complement Activation Products (CB-CAPs) technology (EC4d and BC4d) integrated with eight autoantibodies.
• T-Cell Biomarkers: Development and commercialization of T-Cell Biomarkers (TC4d, TIgG, and TIgM) for enhanced SLE sensitivity, licensed exclusively from Allegheny Health Network Research Institute (AHN).
• RA Sub-Profile Biomarkers: Development of Anti-RA33 IgA, Anti-RA33 IgG, and Anti-RA33 IgM biomarkers to address the diagnostic gap in seronegative RA.
• PAD4 Biomarkers: Pipeline focus on peptidyl arginine deiminase 4 (PAD4) autoantibodies (anti-PAD4 IgG and IgA) as novel diagnostic and prognostic biomarkers for RA, particularly in seronegative cases.
• SLE Disease Activity: Research into identifying a set of biomarkers to inform an AI-developed algorithm for guiding ongoing treatment decisions and monitoring disease activity in lupus patients.
• RA Disease Activity: Leveraging an extensive biorepository to screen for protein antibody markers to develop an algorithmic solution for predicting RA disease activity.
• Lupus Nephritis Biomarkers: Development of a test for detecting urinary protein analytes to aid in the management and risk stratification of Lupus Nephritis (LN) patients, based on intellectual property licensed from Johns Hopkins University (JHU).
• Kidney Damage Biomarkers: Development of a four-protein blood-based panel for sensitive detection of kidney damage in early LN and diabetic nephropathy, expected for Pharma collaborations in early 2025.

Intellectual Property Portfolio:

• Patent Strategy: Exagen Inc. maintains a portfolio of U.S. and foreign patents and patent applications.
  • AVISE® Lupus Platform: Protected by five issued U.S. patents, three U.S. nonprovisional patent applications, and six foreign patents covering the AVISE® Lupus algorithm, with expirations between 2032 and 2034.
  • T-Cell Biomarkers: Covered by one issued U.S. patent (US 9,709,564) and a foreign patent application in Brazil, with the U.S. patent expiring in 2035.
  • AVISE® MTX: Protected by two U.S. patents (US 7,582,282 and US 7,695,908) related to monitoring methotrexate therapy, expiring in 2026 and 2027, respectively.
• Licensing Programs: The company engages in licensing agreements, including exclusive licenses from AHN and JHU for key technologies.
• IP Litigation: Material disputes are disclosed in the Legal Proceedings section.

Technology Partnerships:

• Strategic Alliances: Exclusive license agreements with Allegheny Health Network Research Institute (AHN) for T-Cell Biomarkers and Johns Hopkins University (JHU) for Lupus Nephritis urinary protein biomarkers.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Exagen Inc. revitalized its senior leadership team in late 2022, including the appointment of its current Chief Executive Officer, Chief Financial Officer, Vice President of Sales, Chief Medical Officer, and Medical and Laboratory Director.

Board Composition: The board of directors includes: Ana Hooker (Senior Vice President, Chief Laboratory Officer, Exact Sciences Corporation), Scott Kahn, Ph.D. (Director, Rady Children's Institute for Genomic Medicine), Paul Kim (Chief Financial Officer, Fulgent Genetics, Inc.), Bruce Robertson, Ph.D. (Managing Director, H.I.G Capital, LLC), and Frank Stokes (Chief Financial Officer, Castle Biosciences, Inc.). The Audit Committee is responsible for overseeing cybersecurity risk management.

Human Capital Strategy

Workforce Composition:

• Total Employees: 209 as of December 31, 2024 (203 full-time, 6 part-time).
• Geographic Distribution: All employees are located in the United States.
• Skill Mix: The workforce is distributed across laboratory operations (57 employees), research and development (13 employees), sales and marketing (59 employees), and general and administrative functions (74 employees).

Talent Management: Acquisition & Retention:

• Hiring Strategy: Exagen Inc. prioritizes attracting, motivating, and retaining talent at all levels, particularly highly skilled scientists (including licensed clinical laboratory scientists and biostatisticians) and specialized salespeople.
• Retention Metrics: Not explicitly disclosed, but the company's efforts include providing competitive compensation and comprehensive benefits packages.
• Employee Value Proposition: The company aims to create an equitable, inclusive, and empowering environment that fosters employee growth and career advancement, emphasizing values such as innovation, passion, data-driven decision making, persistence, and honesty.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed, but the company is committed to building a diverse workforce.
• Development Programs: Sales representatives undergo comprehensive disease-level sales training and are required to participate in regular, ongoing training activities and certifications.
• Culture & Engagement: Focuses on employee retention and engagement to support business operations and protect the long-term interests of securityholders.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Exagen Inc. established an Environmental, Social and Governance Committee (ESG Committee) in 2022. This committee is responsible for reviewing and recommending programs, policies, and practices related to ESG issues, meeting formally at least annually.

Business Cyclicality & Seasonality

Demand Patterns: Exagen Inc. anticipates some seasonal variations in its financial results. These variations are influenced by factors such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers (including medical conferences), climate and weather conditions in its markets (e.g., excess sun exposure causing flares in SLE), seasonal conditions affecting medical practices and provider activity (e.g., influenza outbreaks reducing patient visits), and other factors related to the timing of patient benefit changes, deductibles, and co-insurance limits.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Exagen Inc. operates within a heavily regulated industry, subject to a complex web of federal, state, local, and foreign laws and regulations. Industry-Specific Regulations:

• Clinical Laboratory Regulation: The company's Vista, California laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). It is certified for high-complexity testing by CMS and licensed by California and all states requiring out-of-state licensure, including the NYSDOH, which requires product-specific approval for Laboratory Developed Tests (LDTs).
• FDA Oversight of LDTs: Historically, the FDA exercised enforcement discretion over LDTs. However, a final rule issued in May 2024, effective July 5, 2024, will regulate LDTs under the medical device framework, phasing out enforcement discretion over a four-year period. This could subject Exagen Inc.'s AVISE® tests to extensive medical device regulatory requirements, including premarket clearance or approval. Litigation is ongoing challenging this rule, creating uncertainty regarding its implementation timeline and scope.
• Clinical Trials: The company conducts research studies involving clinical investigators and human subjects, which are subject to extensive federal and institutional regulations, including requirements for Institutional Review Board (IRB) review, informed consent, and timely reporting of adverse events.
• Advertising: Advertising for laboratory services and diagnostic testing products is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC) and comparable state consumer protection laws.
• Fraud and Abuse Laws: The company is subject to federal physician self-referral prohibitions (Stark Law), federal Anti-Kickback Statute, Eliminating Kickbacks in Recovery Act of 2018 (EKRA), federal False Claims Act, Civil Monetary Penalties Law (CMP Law), and various state anti-kickback, self-referral, fee-splitting, insurance fraud, anti-markup, and direct-bill laws.
• Sunshine Act: The Physician Payments Sunshine Act, which imposes reporting requirements on medical device manufacturers for payments to healthcare practitioners, may become applicable to Exagen Inc. if the FDA actively regulates LDTs as medical devices.
• Information Blocking Rules: The ONC's Information Blocking Rule, effective 2021, prohibits practices likely to interfere with access, exchange, or use of electronic health information, requiring on-demand patient access to laboratory test results.

Trade & Export Controls:

• Export Restrictions: Exagen Inc. is subject to U.S. export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls.
• Sanctions Compliance: The company is also subject to the Foreign Corrupt Practices Act (FCPA), the U.S. domestic bribery statute, the U.S. Travel Act, and the USA PATRIOT Act, as well as other state and national anti-bribery and anti-money laundering laws.

Legal Proceedings:

• Qui Tam Lawsuit: In October 2023, Exagen Inc. resolved an investigation with the U.S. Attorney’s Office for the District of Massachusetts stemming from a qui tam lawsuit. The company made a $0.7 million remittance (plus interest) related to historical specimen processing arrangements. While the "covered conduct" was dismissed with prejudice, non-covered conduct was dismissed without prejudice. A motion to dismiss the remaining complaint is pending as of February 2024, and the company intends to vigorously defend against the claims.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: -0.3% for the year ended December 31, 2024, compared to -0.1% for the year ended December 31, 2023.
• Geographic Tax Planning: Not explicitly detailed beyond federal and state income taxes.
• Tax Reform Impact: Exagen Inc. has undergone ownership changes in 2003, 2008, 2012, 2017, and 2019, as defined by Sections 382 and 383 of the Internal Revenue Code. These changes limit the company's ability to utilize a significant portion of its pre-change net operating loss (NOL) carryforwards and other pre-change tax attributes to offset future taxable income. Federal NOL carryforwards generated after December 31, 2017, carry forward indefinitely but are limited to offsetting 80% of taxable income in taxable years beginning after December 31, 2020.
• NOL Carryforwards: As of December 31, 2024, the company had federal NOL carryforwards of approximately $141.5 million and state NOL carryforwards of $98.7 million. Approximately $43.5 million of federal NOLs will begin to expire in 2025.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Exagen Inc. maintains professional liability insurance to protect against claims alleging errors and omissions or professional liability related to its testing products. It also carries information security risk insurance to provide protection against potential losses arising from cybersecurity incidents.
• Risk Transfer Mechanisms: Not explicitly detailed beyond the mentioned insurance coverages.